跳至主要内容
临床试验/NCT02019433
NCT02019433终止不适用

Post Market Clinical Follow-Up of Acetabular Titan-Augment Structan®

Aesculap AG3 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2012年7月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
Aesculap AG
入组人数
5
试验地点
3
主要终点
Implant Survival Rates

研究概览

简要总结

Implant Survival as well as clinical and radiological Follow-Up of acetabular Titan-Augment Structan®

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Minimum age 18 years
  • Indication for cementless hip arthroplasty with acetabular defects that need Allograft or titanium augment
  • Patient consent for study participation
  • Physical and mental willingness to participate in the follow-ups

排除标准

  • Patient not available for follow-up
  • Increased anesthetics risks for the patient according to the "American Society of Anesthesiology": ASA IV
  • Alcohol- or Drug abuse
  • Permanent cortisone therapy
  • Clinically relevant infection
  • (Planned) pregnancy

结局指标

主要结局

Implant Survival Rates

时间窗: 12 months

Implant survival is analysed at follow-up examinations at 3 and 12 months

次要结局

  • Pain(3 and 12 months)
  • Implant Position(3 and 12 months)
  • Osteolysis(3 and 12 months)
  • Ossifications(3 and 12 months)
  • Clinical Outcome(3 and 12 months)
  • Migration of Structan®(3 and 12 months)

研究者

发起方
Aesculap AG
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验